Our experts review real-world strategies for patients with statin intolerance and an anticipated new therapy that doesn’t cause muscle symptoms.
The unprecedented reduction of LDL cholesterol will be the No. 4 most influential medical innovation for 2018, predict experts at Cleveland Clinic.
As the dust settles in the wake of the FOURIER trial results, how should we translate them into practice? Dr. Steven Nissen shares his thoughts on this, as well as PCSK9 inhibitor safety, in this two-minute video.